Details

Some $91 billion was spent on cancer drugs last year, while it takes 10 to 15 years and up to $1.2 billion to bring a new cancer drug to market. Are big pharma companies, each competing for a piece of the therapy pie, the best home for drug development? Where do venture-funded drug companies fit? How can research and development better collaborate? And while there are still gaps in the FDA drug-approval process, is a more streamlined approval process the key to a better discovery approach?

– Martha Donoghue, Clinical Reviewer, Hematology and Oncology Products, US Food and Drug Administration
– Mitchell H. Gold, Executive chairman, Alpine Immune Sciences; Founder and managing partner, Alpine BioVentures
– John Lin, Chief scientific officer, Oncology-Rinat, Pfizer Worldwide Research and Development
– Krishna Yeshwant, General partner, Google Ventures
– Moderator: Vivek Muthu, Chief health advisor, Economist Intelligence Unit